2563 logo

Beijing Biostar Pharmaceuticals SEHK:2563 Stock Report

Last Price

HK$32.75

Market Cap

HK$12.0b

7D

-7.6%

1Y

n/a

Updated

24 Dec, 2024

Data

Company Financials +

Beijing Biostar Pharmaceuticals Co., Ltd.

SEHK:2563 Stock Report

Market Cap: HK$12.0b

2563 Stock Overview

A synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China. More details

2563 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Beijing Biostar Pharmaceuticals Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Beijing Biostar Pharmaceuticals
Historical stock prices
Current Share PriceHK$32.75
52 Week HighHK$39.50
52 Week LowHK$19.48
Beta0
1 Month Change13.32%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO57.45%

Recent News & Updates

Recent updates

Shareholder Returns

2563HK BiotechsHK Market
7D-7.6%-2.3%2.3%
1Yn/a-6.0%22.4%

Return vs Industry: Insufficient data to determine how 2563 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 2563 performed against the Hong Kong Market.

Price Volatility

Is 2563's price volatile compared to industry and market?
2563 volatility
2563 Average Weekly Movement11.5%
Biotechs Industry Average Movement11.5%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.5%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 2563 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: Insufficient data to determine 2563's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/aRongguo Qiuwww.biostar-pharm.com

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the research and development, production, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injection, a microtubule inhibitor for the treatment of metastasis breast cancer, advanced non-small cell lung cancer, solid tumor, and Glioblastoma. It also engages in the development of Utidelone oral capsule that is in phase II/III clinical trials; Utidelone nano formulation; and Utidelone antibody drug conjugate, as well as other active pharmaceutical ingredients, such as BG22, BG18 and BG44.

Beijing Biostar Pharmaceuticals Co., Ltd. Fundamentals Summary

How do Beijing Biostar Pharmaceuticals's earnings and revenue compare to its market cap?
2563 fundamental statistics
Market capHK$11.99b
Earnings (TTM)-HK$201.86m
Revenue (TTM)HK$70.93m

168.3x

P/S Ratio

-59.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2563 income statement (TTM)
RevenueCN¥66.64m
Cost of RevenueCN¥19.81m
Gross ProfitCN¥46.83m
Other ExpensesCN¥236.47m
Earnings-CN¥189.64m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin70.27%
Net Profit Margin-284.60%
Debt/Equity Ratio0%

How did 2563 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:46
End of Day Share Price 2024/12/24 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Biostar Pharmaceuticals Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhishun SiuCCB International Securities Limited